Tor Biering-Sørensen clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   DAN-ZOSTER · Recombinant Herpes Zoster Vaccine · Cardiovascular…DAN-ZOSTER · Recombinant Herpes Zoster Vaccine · Cardiovascular Events and Dementia

   Enrollment closed, study ongoing

   Also in this update: Primary and study completion pushed from Apr 2029 to Jun 2029

   Tor Biering-Sørensen·Phase 4· NCT07485283· Registry history of NCT07485283 on ClinicalTrials.gov (opens the registry)

   Updated Oct 14, 2026

2. Minor

   DAN-COVID · MRNA-1273 Variant-Containing Vaccine Formulation…DAN-COVID · MRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

   Trial completed

   Also in this update: Final enrollment: 41060 participants (planned 285000)

   Tor Biering-Sørensen·Phase 4· NCT07279766· Registry history of NCT07279766 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.